Age-related differences in presentation and outcomes of anti-VEGF treatment of retinal vein occlusion.
Can J Ophthalmol
; 56(2): 96-104, 2021 04.
Article
em En
| MEDLINE
| ID: mdl-33039322
ABSTRACT
OBJECTIVE:
To assess age-related differences at baseline and treatment outcomes in patients with retinal vein occlusion (RVO) and macular edema treated with anti-vascular endothelial growth factor (VEGF) therapyDESIGN:
Single-centre retrospective chart review.PARTICIPANTS:
295 treatment-naïve RVO patients.METHODS:
295 RVO patients included were separated into age quartiles group A (22-61 years), group B (62-70 years), group C (71-79 years), and group D (80-95 years). Outcomes including central subfield thickness (CST), cubic volume, cubic average thickness, and visual acuity (VA) were collected at baseline and at 6 and 12 months after treatment. The primary outcome of the study was the CST at 12 months after anti-VEGF therapy.RESULTS:
Mean baseline CST for groups A, B, C, and D was 406.3 ± 161.2 µm, 463.4 ± 165.5 µm, 470.6 ± 187 µm, and 427.3 ± 187.2 µm, respectively. No significant differences in CST were observed between groups at baseline, 6 months, or 12 months (p ≥ 0.08). Mean baseline VA for groups A, B, C, and D was 55.8 ± 19.5, 54.4 ± 19.8, 54.7 ± 19, and 51.4 ± 20.4 Early Treatment Diabetic Retinopathy letters, respectively. VA did not differ significantly between age groups at baseline, 6 months, or 12 months (p ≥ 0.06).CONCLUSIONS:
The presentation of RVO and the visual outcomes of anti-VEGF therapy do not vary based on age.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Oclusão da Veia Retiniana
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
Limite:
Adult
/
Humans
/
Infant
/
Middle aged
Idioma:
En
Revista:
Can J Ophthalmol
Ano de publicação:
2021
Tipo de documento:
Article